The second and much broader tranche of the United States Section 232 tariffs on patented pharmaceuticals takes effect on September 29, 2026, extending duties of up to 100% from a named list of 17 large manufacturers to every other company shipping covered products into the country. The first tranche, which applied only to firms identified in Annex III of the April 2 proclamation, has been live since July 31.
For retail, the deadline lands in an awkward place. Pharmacy counters sit inside a large share of American grocery, mass and convenience square footage, and the chains that operate them are already absorbing reimbursement pressure, store closures and a federal drug pricing regime that is compressing branded prices from the other direction.
In short
- September 29, 2026 is the date all remaining importers of patented pharmaceuticals and active pharmaceutical ingredients become subject to Section 232 duties, per the April 2, 2026 presidential proclamation.
- The headline rate is 100% ad valorem, cut to 20% for companies with an approved onshoring plan and to 0% for companies holding both an onshoring agreement and a most favored nation pricing agreement.
- Generics and biosimilars are excluded, which is why the direct volume exposure for US retail pharmacy is far smaller than the headline rate implies: the large majority of US scripts dispense generic.
- Country caps blunt the rate sharply: 15% for the EU, Japan, South Korea and Switzerland, 10% for the United Kingdom, against 100% for everywhere else.
- The retail read-through is already visible: Walmart reported US comparable sales up 2.6% in Q2, but 3.4% excluding health and wellness, a gap its finance chief attributed to drug pricing regulation.
What actually changes on September 29
The proclamation signed on April 2, 2026 invoked Section 232 of the Trade Expansion Act of 1962, the same national security authority used for steel, aluminum, copper and, more recently, unmanned aircraft systems. It set two start dates rather than one.
The first applied on July 31, 2026 and was narrow by design. It captured only the manufacturers named in Annex III of the proclamation, a group of large branded pharmaceutical companies that the administration had already been negotiating with over domestic manufacturing commitments and drug pricing.
The second start date is September 29, 2026. From that point the tariff applies to all other affected companies, which in practice means the long tail of mid-size and smaller branded manufacturers, specialty importers, contract manufacturers shipping active pharmaceutical ingredients, and any distributor or retailer acting as importer of record on covered goods.
That structure gave the smaller cohort roughly a 180-day runway from the proclamation to negotiate an onshoring arrangement, restructure a supply chain, or accept the duty. According to trade advisories tracking the measure, that runway closes at the end of September with no indication of a further extension.
The use of Section 232 for medicines rests on a supply chain concentration argument rather than a conventional defence one. Successive US reviews have flagged how much finished branded product and how many active pharmaceutical ingredients originate from a small number of foreign manufacturing clusters, and the proclamation frames domestic capacity as a national security interest on that basis.
That framing is what gives the measure its unusual shape. A conventional tariff aims to reprice imports; this one is explicitly built to be avoided, with tiered discounts that pay manufacturers for building American capacity and for cutting American list prices. The revenue is a secondary objective.
Why the gap between the two dates matters operationally
The transition window created a reporting quirk that importers have been living with since July 31. Per US Customs and Border Protection guidance issued as CSMS #69395344, importers of patented products from non-Annex III companies have had to report Chapter 99 provision 9903.04.61 on entries during the July 31 to September 28 window even though the duty rate was zero.
In other words, the data collection started two months before the money did. CBP has been building an entry-level picture of who imports what, from which manufacturer, under which classification, before the duty switches on for the wider group. Importers who filed sloppily during the zero-rate window have effectively pre-registered their own exposure.
That is a familiar pattern in the 2026 tariff program. The agency has been tightening the identity and data layer around entry filings all year, including a move to void importer of record numbers with inaccurate Form 5106 details from September 18, eleven days before the pharmaceutical tranche lands.
How the tariff tiers actually work
The rate a given shipment pays is not a single number. It is the lowest applicable rate among several overlapping tiers, which is how a 100% headline duty can resolve to nothing at the border for some importers and to a doubling of landed cost for others.
The 100% base rate
The default is a 100% ad valorem duty on covered patented pharmaceutical products and their active pharmaceutical ingredients. Ad valorem means the duty is calculated on declared customs value, so a $1 million entry of a covered branded product carries a $1 million duty on top of any normal customs duty that already applies.
Critically, the Section 232 duty applies in addition to normal customs duties, including on products that would otherwise qualify for preferential treatment under a free trade agreement. A USMCA or other preference claim reduces the ordinary duty but does not switch off the Section 232 layer.
The 20% onshoring rate
Companies with an approved onshoring plan pay 20% instead of 100%. The proclamation sets that reduced rate to run from September 29, 2026 and escalate back to 100% on April 2, 2030, which gives participants a defined multi-year window to move manufacturing capacity into the United States before the discount expires.
The Secretary of Commerce is responsible for publishing the qualifying criteria in the Federal Register. Participating companies must submit periodic progress reports and may be required to undergo external audits, and the proclamation reserves the right to reimpose the full tariff retroactively as well as prospectively where a company fails to deliver on its commitments.
The 0% MFN rate
The deepest concession sits with companies that hold both an onshoring agreement and a most favored nation drug pricing agreement, which the administration has been signing with manufacturers through 2025 and 2026. That combination produces a 0% rate, running through January 20, 2029.
Companies that entered into an MFN agreement prior to April 2, 2026 and appear in Annex II of the proclamation are exempt from duty outright. This is the mechanism that ties trade policy to domestic drug pricing policy: manufacturers effectively trade lower US list prices for tariff relief.
| Tier | Rate | Effective from | Expires or escalates |
|---|---|---|---|
| Annex III companies, no agreement | 100% | July 31, 2026 | No stated end |
| All other companies, no agreement | 100% | September 29, 2026 | No stated end |
| Approved onshoring plan | 20% | September 29, 2026 | Escalates to 100% on April 2, 2030 |
| Onshoring plus MFN pricing agreement | 0% | July 31, 2026 | Through January 20, 2029 |
| Annex II, pre-April 2 MFN agreement | Exempt | July 31, 2026 | Per agreement terms |
What is excluded, and why that decides the retail impact
The exclusion list is the single most important detail for anyone modelling the effect on a pharmacy counter, and it is routinely lost in coverage that leads with the 100% number.
Generic pharmaceutical products and biosimilars are expressly excluded, along with their associated ingredients. So are orphan designated drugs where all indications carry orphan designation, nuclear medicines, plasma derived therapies, fertility treatments, cell and gene therapies, antibody drug conjugates, medical countermeasures related to chemical, biological, radiological and nuclear threats, animal health pharmaceuticals under a qualifying trade framework, and US origin pharmaceutical products.
Generics dominate American dispensing volume. The large majority of prescriptions filled at US retail pharmacies are generic, which means the tariff misses most of what actually crosses a pharmacy counter by script count. What it does not miss is the branded and specialty tail, which carries a disproportionate share of revenue per unit.
The volume versus value split
This creates a split that retail operators will feel differently depending on their mix. A high volume, high generic pharmacy in a mass or grocery format sees limited direct duty exposure on the goods it dispenses. A pharmacy weighted toward branded specialty therapies sees the opposite.
The second-order effect is broader. Manufacturers facing a 100% duty on imported branded product have three levers: absorb it, raise US list prices, or restructure supply. Any list price increase flows into pharmacy acquisition cost, and pharmacy reimbursement does not reprice at the same speed.
Which country caps blunt the rate
Origin matters as much as company status. Products from countries that concluded trade frameworks with the United States face materially lower rates than the 100% default, and those caps cover a large share of branded pharmaceutical imports into the US market.
| Origin | Section 232 pharma rate | Note |
|---|---|---|
| European Union member states | 15% | Covers Ireland, Germany, Denmark, Belgium manufacturing hubs |
| Japan | 15% | Trade framework rate |
| South Korea | 15% | Trade framework rate |
| Switzerland and Liechtenstein | 15% | Major branded and API origin |
| United Kingdom | 10% | Proclamation contemplates reduction to 0% under a future agreement |
| All other origins | 100% | Unless onshoring or MFN tier applies |
Ireland, Switzerland and Denmark are among the largest sources of branded pharmaceutical product entering the United States, so a 15% cap over those origins does far more to contain the aggregate cost than the headline rate suggests. The 100% figure bites hardest on origins outside the framework set.
This is the same design logic visible across the administration’s 2026 trade program, where headline rates are set high and then negotiated down by country and by sector. The pattern repeated in the USTR excess capacity action that caps the China rate and in the sectoral proclamations that preceded it.
How CBP is operating the tariff at the border
The mechanics sit in Harmonized Tariff Schedule Chapters 29 and 30, which cover organic chemicals and pharmaceutical products respectively. That scope captures finished patented pharmaceuticals, active pharmaceutical ingredients and key starting materials.
Importers moving goods in those chapters must report the applicable Chapter 99 HTSUS provision on every entry. Getting that classification wrong is not a cosmetic error: it determines whether duty is assessed, at what rate, and whether the entry is flagged for review.
Foreign trade zones and drawback
Two provisions matter for anyone running inventory through a bonded structure. Entries into a foreign trade zone on or after the effective date must be admitted under Privileged Foreign Status, which locks in the tariff classification and rate at admission and preserves duty liability when the goods enter domestic commerce. The FTZ is therefore a cash flow tool here, not a tariff avoidance tool.
Drawback is available on these duties, which is meaningful for importers who re-export a portion of covered inventory. That is a narrow benefit for retail pharmacy, which dispenses domestically, but a real one for distributors with international flows.
Where multiple rates collide
Per CBP guidance, where more than one rate could apply to the same entry, the lowest applicable rate governs. That resolves the obvious conflict between a country cap and a company tier: a manufacturer with an approved onshoring plan importing from an EU member state does not pay 20% plus 15%, it pays the lower of the two.
Enforcement risk sits alongside the rate risk. The agency has been widening its penalty and seizure posture through 2026, including a broadening of seizure powers with a 50% penalty floor from September 1, which raises the cost of misclassification well beyond the unpaid duty itself.
What retail pharmacy actually pays
Retail pharmacy is rarely the importer of record on branded pharmaceuticals. Product typically enters through the manufacturer or an authorised distributor, and the chain buys domestically. The duty therefore reaches the retailer as acquisition cost, not as a customs bill.
That distinction matters for how quickly the effect shows up. A tariff paid at the border on September 29 flows into wholesale acquisition cost over weeks, then into pharmacy gross margin over the following quarters, filtered by contract terms and by how reimbursement formulas respond to a changed list price.
The reimbursement squeeze
The sector was already under pressure before this. Persistent reimbursement compression on prescription margins, rising operating costs and shifting consumer habits have driven several years of footprint reduction across US pharmacy retail.
Walgreens has closed 18 locations so far in 2026 and expects to shut roughly 100 nationwide as it reshapes the business, with its global finance chief describing the criteria as cash flow negative locations, underperforming owned stores, and leases coming due in the next few years. CVS closed about 270 stores in 2025, following roughly 900 closures across 2022 to 2024, and has since acquired 63 former Rite Aid and Bartell Drugs stores in Idaho, Oregon and Washington plus the prescription files of 626 former Rite Aid and Bartell pharmacies across 15 states. Rite Aid no longer operates as a physical chain.
Front of store is the real retail exposure
For a retail news audience the more consequential channel is footfall rather than dispensing margin. The pharmacy counter is a traffic driver for the aisles around it, and pharmacy visits convert into general merchandise and grocery baskets.
Anything that raises the out of pocket cost of a branded prescription, or that pushes a patient toward a manufacturer direct to consumer channel, removes a trip from the store. That is the mechanism retail investors should be watching, and it is largely independent of whether the retailer ever pays a cent of duty.
The direct to consumer channel is the bigger structural threat
Sitting behind the tariff is a parallel policy track that reaches retail more directly. TrumpRx, the federal direct to consumer drug platform, launched on February 5, 2026 as a hub that points patients toward manufacturer discount programmes rather than selling medicines itself.
The tie to trade policy is explicit. Several of the manufacturer agreements announced with the administration pair a commitment to launch new drugs at most favored nation prices, and to make lower prices available through a direct to consumer route, with relief from the pharmaceutical tariffs. As of February 2026, 16 manufacturers had announced such deals, and by February 20 the platform listed 43 medications from five manufacturers.
For most of the advertised drugs, the platform lets consumers print manufacturer coupons for use at a retail counter, and commonly participating pharmacies include CVS, Walgreens, Walmart, Kroger, Albertsons, Costco and a long tail of independents. That version of the model keeps the trip in the store.
The version that does not keep the trip in the store is a manufacturer shipping direct to the patient. Every branded script that migrates to a manufacturer’s own fulfilment removes a pharmacy visit, and with it the basket that a pharmacy visit generates. The tariff tier structure actively rewards manufacturers for building exactly that channel, which is why the September 29 deadline matters to general merchandise buyers and not only to pharmacy directors.
| Retail channel | Direct duty exposure | Indirect exposure |
|---|---|---|
| Chain drug (CVS, Walgreens) | Low, rarely importer of record | High: acquisition cost, footfall, specialty mix |
| Mass and club (Walmart, Costco) | Low | Moderate: pharmacy is a traffic driver into general merchandise |
| Grocery pharmacy (Kroger, Albertsons) | Low | Moderate: basket attachment on pharmacy trips |
| Online and mail pharmacy | Low | Moderate: branded price sensitivity, DTC substitution |
| Specialty distributors | High where importer of record | High: branded and API concentration |
Why Walmart’s second quarter already shows the mechanism
The clearest evidence that drug pricing policy moves retail numbers came from Walmart’s most recent quarter, reported on August 20. US comparable sales grew 2.6%, but excluding health and wellness they grew 3.4%.
Finance chief John David Rainey attributed the drag to maximum fair price drug regulations. That is a different policy instrument from the Section 232 tariff, but it demonstrates the same transmission path: a federal price intervention on pharmaceuticals showing up directly in a mass retailer’s comparable sales line.
The rest of the quarter was strong. Revenue rose 5.9% to $187.9 billion, operating income jumped 28.8% to $9.4 billion, e-commerce sales grew 24% and now represent over 23% of the Walmart US mix, double the share of five years ago. The company raised fiscal 2027 net sales guidance to 4% to 5% from 3.5% to 4.5%.
Walmart also confirmed it had received substantially all of the $2.9 billion in anticipated tariff refunds following the Supreme Court decision against the IEEPA tariffs, money it has been channelling into price investment rather than margin. The symmetry is worth noting: the same retailer is banking a windfall from one tariff programme being struck down while a different tariff programme expands.
How this stacks on the rest of the 2026 tariff program
Section 232 pharmaceuticals is not arriving into a clean tariff environment. It is one more layer on a schedule that has been thickening all year, and importers have to model the stack rather than any single measure.
Steel, aluminium and copper Section 232 duties were modified by proclamation on April 2, 2026 and took effect on April 6, with the Bureau of Industry and Security running a comment process through August 27 on expanding the covered derivative product list. Section 232 duties on unmanned aircraft systems follow on September 3.
The IEEPA vacuum is why Section 232 keeps expanding
The wider context is that the Supreme Court struck down the IEEPA tariffs in February 2026, ruling that the statute did not authorise the President to impose tariffs of indefinite scope. That decision removed the broadest instrument in the programme and triggered a refund process that CBP is still administering through its Consolidated Administration and Processing of Entries tool.
What followed was a rebuild on narrower but more durable statutory footings: Section 232 for sectoral measures, Section 301 for country and practice specific actions, and Section 338 for retaliation. Each requires more process than IEEPA did, which is precisely why the 2026 measures arrive with proclamations, annexes, comment dockets and staggered effective dates rather than overnight.
For importers the practical consequence is that the tariff landscape is now a calendar rather than a level. Dates matter more than rates, because most of these measures phase in by tranche.
On the country side, the United States imposed 50% Section 338 duties on certain Canadian goods, a measure that overrides USMCA preference for covered products, and Canada responded with retaliatory duties of 15% to 50% on more than 700 US origin products from September 8.
| Measure | Authority | Key date | Rate |
|---|---|---|---|
| Patented pharmaceuticals, tranche 1 | Section 232 | July 31, 2026 | Up to 100% |
| Patented pharmaceuticals, tranche 2 | Section 232 | September 29, 2026 | Up to 100% |
| Unmanned aircraft systems | Section 232 | September 3, 2026 | Per proclamation |
| Certain Canadian goods | Section 338 | August 2026 | 50% |
| Canadian retaliation | Canadian order | September 8, 2026 | 15% to 50% |
| Importer of record voiding | CBP Form 5106 | September 18, 2026 | Not a duty, an entry block |
What importers and retailers should do before September 29
The compliance work is unglamorous and mostly about data quality, because the rate outcome depends on facts that live in the entry filing rather than on negotiation at the port.
- Confirm whether any entity in the group is importer of record on Chapter 29 or Chapter 30 goods. Many retailers assume they are not and discover a specialty or private label flow that says otherwise.
- Map every covered SKU to manufacturer identity, patent status, and country of origin, because those three fields determine which tier applies.
- Check the exclusion list line by line. Generic, biosimilar, orphan, plasma derived, cell and gene, and US origin status all remove product from scope entirely.
- Verify Chapter 99 reporting on entries filed during the July 31 to September 28 zero-rate window, since those filings are already in CBP’s hands.
- Reconcile Form 5106 records before September 18, given the separate importer of record voiding regime taking effect that day.
- Model acquisition cost scenarios at the 100%, 20%, 15%, 10% and 0% tiers rather than at a single point estimate, and stress the branded specialty tail specifically.
- Review FTZ admissions policy, since Privileged Foreign Status is mandatory for covered goods admitted on or after the effective date.
Retailers without direct import exposure still have work to do on the commercial side: renegotiating supply terms, reviewing which branded lines carry enough margin to survive an acquisition cost increase, and modelling the footfall effect if patients migrate toward manufacturer direct channels. The full text of the measure is published on the White House presidential actions page.
What to watch after the deadline
Three signals will indicate whether the September 29 tranche is biting or whether the tier structure has absorbed most of it.
The first is the pace of onshoring agreements. Every additional manufacturer that signs converts a 100% exposure into a 20% or 0% exposure, and the aggregate revenue collected under the measure will say more than the headline rate does.
The second is branded list price behaviour into the fourth quarter and into January 2027, the traditional US price adjustment window. A tariff that manufacturers absorb looks very different from one they pass through.
The third is pharmacy footfall and front of store comparable sales at the mass and grocery chains. If health and wellness continues to run below the rest of the basket at Walmart and its peers, the policy channel into retail is widening rather than closing.
A fourth signal is worth adding for anyone tracking the customs side rather than the retail side. Section 232 has become the administration’s default instrument, and each new sectoral proclamation follows the same template of a high headline rate, an annex of named companies, a staggered effective date and a set of negotiated country caps. Pharmaceuticals is the most complex application of that template so far, and how cleanly it operates from September 29 will shape whether the model is reused for further consumer goods categories.
Frequently asked questions
What exactly happens on September 29, 2026?
Section 232 tariffs on patented pharmaceutical products and active pharmaceutical ingredients extend from the manufacturers named in Annex III of the April 2, 2026 proclamation to all other affected companies. The base rate is 100% ad valorem unless a lower tier applies.
Are generic drugs affected?
No. Generic pharmaceutical products and biosimilars are expressly excluded, along with their associated ingredients. Because generics account for the large majority of US retail prescription volume, most of what a pharmacy dispenses falls outside the measure.
Does a free trade agreement remove the duty?
No. The Section 232 duty applies in addition to normal customs duties, including on goods that qualify for preferential treatment under a free trade agreement. A preference claim reduces the ordinary duty only.
How can a company get below 100%?
Three routes. An approved onshoring plan gives 20% until it escalates to 100% on April 2, 2030. An onshoring agreement combined with a most favored nation pricing agreement gives 0% through January 20, 2029. Country of origin caps of 15% for the EU, Japan, South Korea and Switzerland, and 10% for the United Kingdom, apply independently.
Which rate applies if several could?
Per CBP guidance, where multiple rates could apply to the same entry, the lowest applicable rate governs. A company tier and a country cap do not stack on top of one another.
Do retailers pay this duty directly?
Usually not. Retail pharmacy is rarely the importer of record on branded pharmaceuticals, which typically enter through the manufacturer or an authorised distributor. The cost reaches retailers through wholesale acquisition cost instead, and shows up over quarters rather than at the border.
What HTS classifications are in scope?
Harmonized Tariff Schedule Chapters 29 and 30, covering organic chemicals and pharmaceutical products. That captures finished patented pharmaceuticals, active pharmaceutical ingredients and key starting materials. Importers must report the applicable Chapter 99 provision on entry.
Is there any duty relief for re-exported product?
Drawback is available on these duties, which helps distributors with international flows. Foreign trade zone admissions on or after the effective date must use Privileged Foreign Status, so an FTZ defers rather than avoids the liability.
Is there evidence drug policy already moves retail results?
Yes. Walmart reported US comparable sales up 2.6% in its most recent quarter but 3.4% excluding health and wellness, a gap its finance chief attributed to maximum fair price drug regulations. That is a different instrument from the tariff, but it demonstrates the same transmission into retail comparable sales.